Published in Curr Drug Targets on September 01, 2011
Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis. Aliment Pharmacol Ther (2012) 1.53
JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol (2015) 0.93
Laparoscopic surgery for ulcerative colitis: a review of the literature. Surg Today (2014) 0.90
Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis. Dig Dis Sci (2015) 0.78
Minimally invasive surgery for inflammatory bowel disease: Review of current developments and future perspectives. World J Gastrointest Pharmacol Ther (2016) 0.75
A retrospective analysis of 20-year data of the surgical management of ulcerative colitis patients in Taiwan: a study of Taiwan Society of Inflammatory Bowel Disease. Intest Res (2016) 0.75
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet (2009) 5.03
A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. Nat Genet (2011) 3.59
Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA (2008) 3.09
Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology (2012) 2.95
Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology (2013) 2.78
Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol (2012) 2.73
Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol (2009) 2.27
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc Natl Acad Sci U S A (2011) 2.12
Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol (2013) 2.05
Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med (2014) 2.04
Retracted A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Am J Gastroenterol (2008) 2.04
Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol (2002) 1.97
Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut (2012) 1.97
Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease. Gut (2010) 1.93
Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut (2010) 1.87
Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol (2013) 1.86
Fibrin glue is effective healing perianal fistulas in patients with Crohn's disease. Gastroenterology (2010) 1.73
Estrogen alters hippocampal dendritic spine shape and enhances synaptic protein immunoreactivity and spatial memory in female mice. Proc Natl Acad Sci U S A (2004) 1.72
Long-term follow-up of patients on home parenteral nutrition in Europe: implications for intestinal transplantation. Gut (2010) 1.61
The Rho-specific GEF Lfc interacts with neurabin and spinophilin to regulate dendritic spine morphology. Neuron (2005) 1.57
Spinophilin facilitates dephosphorylation of doublecortin by PP1 to mediate microtubule bundling at the axonal wrist. Cell (2007) 1.56
Preventing postoperative recurrence in Crohn's disease: what does the future hold? Drugs (2013) 1.55
Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol (2010) 1.54
H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut (2011) 1.52
Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors. Science (2004) 1.52
Malnutrition is an independent factor associated with nosocomial infections. Br J Nutr (2004) 1.51
Estrogen increases the number of spinophilin-immunoreactive spines in the hippocampus of young and aged female rhesus monkeys. J Comp Neurol (2003) 1.49
Candidates for intestinal transplantation: a multicenter survey in Europe. Am J Gastroenterol (2006) 1.49
Gastric pouch resizing for Roux-en-Y gastric bypass failure in patients with a dilated pouch. Surg Obes Relat Dis (2012) 1.49
Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis (2013) 1.49
Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol (2011) 1.49
Estrogen replacement increases spinophilin-immunoreactive spine number in the prefrontal cortex of female rhesus monkeys. Cereb Cortex (2004) 1.48
The pig as a preclinical model for intestinal ischemia-reperfusion and transplantation studies. J Surg Res (2012) 1.44
Survival of patients identified as candidates for intestinal transplantation: a 3-year prospective follow-up. Gastroenterology (2008) 1.43
Preoperative magnetic resonance enterography in predicting findings and optimizing surgical approach in Crohn's disease. J Gastrointest Surg (2013) 1.42
Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn's disease. Inflamm Bowel Dis (2015) 1.38
Spinophilin regulates Ca2+ signalling by binding the N-terminal domain of RGS2 and the third intracellular loop of G-protein-coupled receptors. Nat Cell Biol (2005) 1.36
Multiple actions of spinophilin regulate mu opioid receptor function. Neuron (2008) 1.30
Spinophilin/neurabin reciprocally regulate signaling intensity by G protein-coupled receptors. EMBO J (2007) 1.29
Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol (2011) 1.26
The role of clips in preventing migration of fully covered metallic esophageal stents: a pilot comparative study. Surg Endosc (2011) 1.26
Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis (2010) 1.26
Nutritional deficiencies in patients with Crohn's disease in remission. Inflamm Bowel Dis (2006) 1.26
Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease. PLoS One (2009) 1.24
Postoperative recurrent luminal Crohn's disease: a systematic review. Inflamm Bowel Dis (2011) 1.24
Phosphorylation of spinophilin modulates its interaction with actin filaments. J Biol Chem (2002) 1.23
A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol (2010) 1.22
Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut (2013) 1.22
VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. J Clin Invest (2014) 1.20
Differential expression and regulation of ADAM17 and TIMP3 in acute inflamed intestinal epithelia. Am J Physiol Gastrointest Liver Physiol (2009) 1.18
PNUTS, a protein phosphatase 1 (PP1) nuclear targeting subunit. Characterization of its PP1- and RNA-binding domains and regulation by phosphorylation. J Biol Chem (2003) 1.17
Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol (2010) 1.15
Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD). Dig Liver Dis (2012) 1.12
Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med (2013) 1.08
Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis (2011) 1.07
Dietary beliefs and behavior among inflammatory bowel disease patients. Inflamm Bowel Dis (2013) 1.07
Adrenergic modulation of NMDA receptors in prefrontal cortex is differentially regulated by RGS proteins and spinophilin. Proc Natl Acad Sci U S A (2006) 1.06
Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis (2013) 1.06
Spinophilin is phosphorylated by Ca2+/calmodulin-dependent protein kinase II resulting in regulation of its binding to F-actin. J Neurochem (2004) 1.06
Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases. World J Gastroenterol (2011) 1.05
Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. Inflamm Bowel Dis (2011) 1.05
Abnormally expressed ER stress response chaperone Gp96 in CD favours adherent-invasive Escherichia coli invasion. Gut (2010) 1.05
Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. J Crohns Colitis (2013) 1.04
Spinophilin stabilizes cell surface expression of alpha 2B-adrenergic receptors. J Biol Chem (2003) 1.03
Amplification loop of the inflammatory process is induced by P2X7R activation in intestinal epithelial cells in response to neutrophil transepithelial migration. Am J Physiol Gastrointest Liver Physiol (2010) 1.03
Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. Curr Drug Targets (2010) 1.01
Diagnostic accuracy of a rapid urine-screening test (Multistix8SG) in cirrhotic patients with spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol (2002) 1.01
Mucosal healing in Crohn's disease: a systematic review. Inflamm Bowel Dis (2013) 0.99
Diagnosis, prevention and treatment of postoperative Crohn's disease recurrence. Dig Liver Dis (2012) 0.99
Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol (2013) 0.98
Arrestins and spinophilin competitively regulate Na+,K+-ATPase trafficking through association with a large cytoplasmic loop of the Na+,K+-ATPase. Mol Biol Cell (2007) 0.98
Alpha 2-adrenergic agonist enrichment of spinophilin at the cell surface involves beta gamma subunits of Gi proteins and is preferentially induced by the alpha 2A-subtype. Mol Pharmacol (2005) 0.98
ESPEN Guidelines on Parenteral Nutrition: gastroenterology. Clin Nutr (2009) 0.97
Surgery for adult Crohn's disease: what is the actual risk? Gut (2011) 0.97
Differential effect of long-term leucine supplementation on skeletal muscle and adipose tissue in old rats: an insulin signaling pathway approach. Age (Dordr) (2011) 0.97
Reduction of cocaine place preference in mice lacking the protein phosphatase 1 inhibitors DARPP 32 or Inhibitor 1. Biol Psychiatry (2002) 0.96
Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis. Inflamm Bowel Dis (2014) 0.96
Chromoendoscopy versus narrow band imaging for colonic surveillance in inflammatory bowel disease. Inflamm Bowel Dis (2013) 0.96
Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep (2013) 0.94
Methyl donor deficiency impairs fatty acid oxidation through PGC-1α hypomethylation and decreased ER-α, ERR-α, and HNF-4α in the rat liver. J Hepatol (2012) 0.93
Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion. J Crohns Colitis (2013) 0.93
Clinical risk factors for complicated disease: how reliable are they? Dig Dis (2013) 0.93
ESPEN Guidelines on Parenteral Nutrition: home parenteral nutrition (HPN) in adult patients. Clin Nutr (2009) 0.93
CT-guided percutaneous catheter drainage of acute infectious necrotizing pancreatitis: assessment of effectiveness and safety. AJR Am J Roentgenol (2012) 0.91
Bacterial sensor triggering receptor expressed on myeloid cells-2 regulates the mucosal inflammatory response. Gastroenterology (2012) 0.90
Phenotype of inflammatory bowel disease at diagnosis in the Netherlands: a population-based inception cohort study (the Delta Cohort). Inflamm Bowel Dis (2013) 0.90
The actin-binding domain of spinophilin is necessary and sufficient for targeting to dendritic spines. Neuromolecular Med (2002) 0.89
Mortality and cancer in pediatric-onset inflammatory bowel disease: a population-based study. Am J Gastroenterol (2013) 0.89
Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment. Curr Drug Targets (2013) 0.89
Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis (2015) 0.88
Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis (2012) 0.88
Effects of total enteral nutrition supplemented with a multi-fibre mix on faecal short-chain fatty acids and microbiota. Clin Nutr (2005) 0.87
Nutritional support during oncologic treatment of patients with gastrointestinal cancer: who could benefit? Cancer Treat Rev (2008) 0.87
Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab. Clin Gastroenterol Hepatol (2013) 0.87
Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis (2011) 0.86
Identification of areas of functioning and disability addressed in inflammatory bowel disease-specific patient reported outcome measures. J Crohns Colitis (2011) 0.86
How NOD2 mutations predispose to Crohn's disease? Microbes Infect (2007) 0.86
Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease. Inflamm Bowel Dis (2009) 0.86